Global dPCR and qPCR Market 2022-2028

Global dPCR and qPCR Market 2022-2028

The global digital PCR (dPCR) and real-time PCR (qPCR) market is estimated to grow at a CAGR of 8.0% during the forecast period. The Polymerase Chain Reaction (PCR) is a technique that is performed in the laboratory to amplify DNA and create copies of DNA in interest. It is used in biological and medical research for different applications that include detecting the presence or absence of gene during infection, generating forensic DNA profiles from samples of DNA and processing DNA for sequencing. The market for dPCR and qPCR is driven by various pivotal factors such as rising demand for precision and personalized medicine, technological advancement in PCR technology, significance of dPCR and qPCR in drug development and clinical diagnostics. In the US, the Personalized Medicine Coalition (PMC) promotes the understanding and adoption of personalized medicine to benefit patients and the healthcare system. PMC supports investment in personalized medicine through education, advocacy, and evidence development. In 2021, National Institutes of Health (NIH) is expected to receive $41.6 billion, a $2.5 billion, or 6.4%, increase over 2021 program level funding. Such grand funding shows growing research programs in the field of precision medicine; hence, this will create demand for molecular diagnostic technologies such as dPCR and qPCR.

Moreover, rapidly transforming microbial research and infectious disease management scenario is further driving the market growth of dPCR and qPCR technologies. The management of infectious diseases is very crucial. The outbreak of infectious diseases can lead to high number of mortalities that put economic burden on the economies. Coronavirus (COVID-19), severe acute respiratory syndrome (SARS), H1N1 or swine flu, and the Ebola virus have caused a large number of mortalities around the globe. Currently, COVID-19 has been found in more than 25 countries and has infected over 50,000 people. It has a mortality rate estimated at 2.0%, causing over 2,000 mortalities till February 2021; this number is increasing extensively every day. In order to diagnose and develop a treatment for such infectious diseases, innovative technologies play an important role. Real-time RT PCR Assays Panel are widely used for the detection of novel coronavirus across the globe. Along with it, dPCR coupled with other new techniques such as Next-Generation Sequencing (NGS) is transforming the microbial research including microbiome sequencing. The combination of speed increased sensitivity, and absolute quantitation of microorganisms is advancing in many domains such as pathogen identification and detection, public health, epidemiology, phylogeny, characterization of the composition, and changes in microbiomes. Therefore, the growing microbiome sequencing industry will positively influence the demand for dPCR and qPCR technologies. The need for innovative techniques for early detection and diagnosis of treatment has led several market players to focus on the development of microbiome sequencing.

Market players are engaged in collaborating artificial intelligence (AI) with microbiome sequencing to promote studies on gut microbiomes. For instance, in 2021, Viome, Inc. developed ‘Vie’, a company’s AI system, that uses data gathered from four sources including biological testing, expert knowledge, customer feedback, and scientific literature. Moreover, the increasing healthcare spending on promoting microbiome research in numerous countries is expected to promote the growth of the market in near future. For instance, one such initiative, taken by NIH, is the integrated Human Microbiome Project (HMP) which began in 2007 as an extension of the Human Genome Project. The project was initiated for enhancing the research on microbiomes in the US. Additionally, the cost associated with the sequencing technologies has decreased in the past years; this is expected to be one of the prime reasons that are expected to promote the growth of the market over the forecast period.